Cellular immune responses in humans induced by two serogroup B meningococcal outer membrane vesicle vaccines given separately and in Combination

Clinical and Vaccine Immunology

Volumn 23, Issue 4, 2016, Pages 353-362

  Oftung, Fredrik ^a   Korsvold, Gro Ellen ^a   Aase, Audun ^a   Næss, Lisbeth M ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

MENBVAC VACCINE; MENINGOCOCCUS VACCINE; MENZB VACCINE; UNCLASSIFIED DRUG; CYTOKINE;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL OUTER MEMBRANE; BACTERIAL STRAIN; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS REACTION; CYTOKINE RELEASE; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; IMMUNOPHENOTYPING; LYMPHOCYTE PROLIFERATION; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NORMAL HUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; CELL PROLIFERATION; CELLULAR IMMUNITY; EXOSOME; HETEROLOGOUS IMMUNITY; IMMUNIZATION; IMMUNOLOGY; SECRETION (PROCESS);

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYTOKINES; EXTRACELLULAR VESICLES; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HETEROLOGOUS; IMMUNIZATION SCHEDULE; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B;

EID: 84964832968     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00666-15     Document Type: Article

References (53)

1. Thornton V, Lennon D, Rasanathan K, O'Hallahan J, Oster P, Stewart J, Tilman S, Aaberge I, Feiring B, Nokleby H, Rosenqvist E, White K, Reid S, Mulholland K, Wakefield MJ, Martin D. 2006. Safety and immunogenicity of New Zealand strain meningococcal serogroup BOMV vaccine in healthy adults: beginning of epidemic control. Vaccine 24: 1395-1400. http://dx.doi.org/10.1016/j.vaccine.2005.09.043.
2. Sierra GV, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, Sotolongo PF, Casanueva GV, Rico CO, Rodriguez CR, Terry MH. 1991. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 14:195-210.
3. Holst J, Oster P, Arnold R, Tatley MV, Naess LM, Aaberge IS, Galloway Y, McNicholas A, O'Hallahan J, Rosenqvist E, Black S. 2013. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): Lessons from past programs and implications for the future. Hum Vaccines Immunother 9:1241-1253. http://dx.doi.org/10.4161/hv.24129.
4. Feavers IM, Pizza M. 2009. Meningococcal protein antigens and vaccines. Vaccine 27(Suppl 2):B42-B50. http://dx.doi.org/10.1016/j.vaccine .2009.05.001.
5. Tappero JW, Lagos R, Ballesteros AM, Plikaytis B, Williams D, Dykes J, Gheesling LL, Carlone GM, Hoiby EA, Holst J, Nokleby H, Rosenqvist E, Sierra G, Campa C, Sotolongo F, Vega J, Garcia J, Herrera P, Poolman JT, Perkins BA. 1999. Immunogenicity of 2 serogroup B outer membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 281:1520-1527.
6. Bjune G, Hoiby EA, Gronnesby JK, Arnesen O, Fredriksen JH, Halstensen A, Holten E, Lindbak AK, Nokleby H, Rosenqvist E. 1991. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338:1093-1096. http://dx.doi.org/10.1016/0140-6736(91)91961-S.
7. Feiring B, Fuglesang J, Oster P, Naess LM, Helland OS, Tilman S, Rosenqvist E, Bergsaker MA, Nokleby H, Aaberge IS. 2006. Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine. Clin Vaccine Immunol 13:790-796. http://dx.doi.org/10.1128/CVI.00047-06.
8. Nokleby H, Feiring B. 1991. The Norwegian meningococcal group B outer membrane vesicle vaccine: side effects in phase II trials. NIPH Ann 14:95-102.
9. Nokleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. 2007. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine 25:3080-3084. http://dx.doi.org/10.1016/j.vaccine.2007.01.022.
10. Caron F, du ChǍtelet IP, Leroy J-P, Ruckly C, Blanchard M, Bohic N, Massy N, Morer I, Floret D, Delbos V, Hong E, Révillion M, Berthelot G, Lemée L, Deghmane A-E, Bénichou J, Lévy-Bruhl D, Taha M-K. 2011. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis 11:455-463. http://dx.doi.org/10.1016/S1473-3099(11)70027-5.
11. Caron F, Delbos V, Houivet E, Deghmane A-E, Leroy J-P, Hong E, Bénichou J, Taha M-K. 2012. Evolution of immune response against Neisseria meningitidis B:14:P1.7,16 before and after the outer membrane vesicle vaccine MenBvac. Vaccine 30:5059-5062. http://dx.doi.org/10.1016/j.vaccine.2012.05.051.
12. Dyet K, Devoy A, McDowell R, Martin D. 2005. New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery. Vaccine 23:2228-2230. http://dx.doi.org/10.1016/j .vaccine.2005.01.050.
13. Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D. 2005. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23:2191-2196. http://dx.doi.org/10.1016/j.vaccine.2005 .01.063.
14. Sexton K, Lennon D, Oster P, Crengle S, Martin D, Mulholland K, Percival T, Reid S, Stewart J, O'Hallahan J. 2004. The New Zealand meningococcal vaccine strategy: a tailor-made vaccine to combat a devastating epidemic. N Z Med J 117:U1015.
15. Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. 2007. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year-olds in New Zealand. Vaccine 25:3075-3079. http://dx.doi.org/10.1016/j.vaccine.2007.01.023.
16. Naess LM, Tangen T, Kristoffersen A-C, Aaberge IS, Høiby EA, Rosenqvist E. 2002. Immunogenicity of a combination of two different outer membrane protein based meningococcal group B vaccines, p 284. Abstracts of the 13th International Neisseria Conference, Oslo, Norway.
17. Moe GR, Zuno-Mitchell P, Hammond SN, Granoff DM. 2002. Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains. Infect Immun 70:6021-6031. http://dx.doi.org/10.1128/IAI.70.11 .6021-6031.2002.
18. Sandbu S, Feiring B, Oster P, Helland OS, Bakke HS, Naess LM, Aase A, Aaberge IS, Kristoffersen AC, Rydland KM, Tilman S, Nokleby H, Rosenqvist E. 2007. Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines. Clin Vaccine Immunol 14:1062-1069. http://dx.doi.org/10.1128/CVI.00094-07.
19. Deasy A, Read RC. 2011. Challenges for development of meningococcal vaccines in infants and children. Expert Rev Vaccines 10:335-343. http://dx.doi.org/10.1586/erv.11.3.
20. Martin NG, Snape MD. 2013. A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn? Expert Rev Vaccines 12:837-858. http://dx.doi.org/10.1586/14760584.2013.814862.
21. O'Ryan M, Stoddard J, Toneatto D, Wassil J, Dull P. 2014. A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program. Drugs 74:15-30. http://dx.doi.org/10.1007/s40265-013-0155-7.
22. Ada GL. 1990. The immunological principles of vaccination. Lancet 335: 523-526. http://dx.doi.org/10.1016/0140-6736(90)90748-T.
23. Abbas AK, Murphy KM, Sher A. 1996. Functional diversity of helper T lymphocytes. Nature 383:787-793. http://dx.doi.org/10.1038/383787a0.
24. Frasch CE, van Alphen L, Holst J, Poolman JT, Rosenqvist E. 2001. Outer membrane protein vesicle vaccines for meningococcal disease. Methods Mol Med 66:81-107. http://dx.doi.org/10.1385/1-59259-148-5:81.
25. Naess LM, Oftung F, Aase A, Michaelsen TE, Pollard AJ. 2001. T-cell responses against meningococcal antigens. Methods Mol Med 66:339-348. http://dx.doi.org/10.1385/1-59259-148-5:339.
26. McHugh S, Deighton J, Rifkin I, Ewan P. 1996. Kinetics and functional implications of Th1 and Th2 cytokine production following activation of peripheral blood mononuclear cells in primary culture. Eur J Immunol 26:1260-1265. http://dx.doi.org/10.1002/eji.1830260612.
27. Al-Attiyah R, El-Shazly A, Mustafa AS. 2012. Comparative analysis of spontaneous and mycobacterial antigen-induced secretion of Th1, Th2, and proinflammatory cytokines by peripheral blood mononuclear cells of tuberculosis patients. Scand J Immunol 75:623-632. http://dx.doi.org/10.1111/j.1365-3083.2012.02692.x.
28. Granoff DM. 2010. Review of meningococcal group B vaccines. Clin Infect Dis 50:S54-S65. http://dx.doi.org/10.1086/648966.
29. Cartwright K, Morris R, Rümke H, Fox A, Ray B, Begg N, Richmond P, Poolman J. 1999. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 17:2612-2619. http://dx.doi.org/10.1016/S0264-410X(99)00044-4.
30. de Kleijn ED, de Groot R, Labadie J, Lafeber AB, van den Dobbelsteen G, van Alphen L, van Dijken H, Kuipers B, van Omme G-W, Wala M, Juttmann R, Rümke HC. 2000. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine 18:1456-1466. http://dx.doi.org/10.1016/S0264-410X(99)00423-5.
31. Boutriau D, Poolman J, Borrow R, Findlow J, Domingo JD, Puig-Barbera J, Baldó JM, Planelles V, Jubert A, Colomer J, Gil A, Levie K, Kervyn A-D, Weynants V, Dominguez F, Barberá R, Sotolongo F. 2007. Immunogenicity and safety of three doses of a bivalent (B:4:P1.19,15 and B:4:P1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin Vaccine Immunol 14:65-73. http://dx.doi.org/10.1128/CVI.00230-06.
32. MacDonald NE, Halperin SA, Law BJ, Forrest B, Danzig LE, Granoff DM. 1998. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA 280:1685-1689. http://dx.doi.org/10.1001/jama.280 .19.1685.
33. Richmond P, Borrow R, Miller E, Clark S, Sadler F, Fox A, Begg N, Morris R, Cartwright K. 1999. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 179:1569-1572. http://dx.doi.org/10.1086/314753.
34. MacLeod MKL, Kappler JW, Marrack P. 2010. Memory CD4 T cells: generation, reactivation and reassignment. Immunology 130:10-15. http://dx.doi.org/10.1111/j.1365-2567.2010.03260.x.
35. Oftung F, Naess LM, Wetzler LM, Korsvold GE, Aase A, Hoiby EA, Dalseg R, Holst J, Michaelsen TE, Haneberg B. 1999. Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine. Infect Immun 67: 921-927.
36. Naess LM, Oftung F, Aase A, Wetzler LM, Sandin R, Michaelsen TE. 1998. Human T-cell responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine. Infect Immun 66:959-965.
37. Haneberg B, Dalseg R, Wedege E, Hoiby EA, Haugen IL, Oftung F, Andersen SR, Naess LM, Aase A, Michaelsen TE, Holst J. 1998. Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect Immun 66:1334-1341.
38. Meiring HD, Kuipers B, van Gaans-van den Brink JA, Poelen MC, Timmermans H, Baart G, Brugghe H, van Schie J, Boog CJ, de Jong AP, van Els CA. 2005. Mass tag-Assisted identification of naturally processed HLA class II-presented meningococcal peptides recognized by CD4T lymphocytes. J Immunol 174:5636-5643. http://dx.doi.org/10.4049/jimmunol.174.9.5636.
39. Davenport V, Guthrie T, Findlow J, Borrow R, Williams NA, Heyderman RS. 2003. Evidence for naturally acquired T cell-mediated mucosal immunity to Neisseria meningitidis. J Immunol 171:4263-4270. http://dx.doi.org/10.4049/jimmunol.171.8.4263.
40. Perez O, Lastre M, Lapinet J, Bracho G, Diaz M, Zayas C, Taboada C, Sierra G. 2001. Immune response induction and new effector mechanisms possibly involved in protection conferred by the Cuban antimeningococcal BC vaccine. Infect Immun 69:4502-4508. http://dx.doi.org/10.1128/IAI.69.7.4502-4508.2001.
41. Wiertz EJ, van Gaans-van den Brink JA, Schreuder GM, Termijtelen AA, Hoogerhout P, Poolman JT. 1991. T cell recognition of Neisseria meningitidis class 1 outer membrane proteins. Identification of T cell epitopes with selected synthetic peptides and determination of HLA restriction elements. J Immunol 147:2012-2018.
42. Wiertz EJ, van Gaans-van den Brink JA, Gausepohl H, Prochnicka-Chalufour A, Hoogerhout P, Poolman JT. 1992. Identification of T cell epitopes occurring in a meningococcal class 1 outer membrane protein using overlapping peptides assembled with simultaneous multiple peptide synthesis. J Exp Med 176:79-88. http://dx.doi.org/10.1084/jem.176.1.79.
43. Wiertz EJ, Delvig A, Donders EM, Brugghe HF, van Unen LM, Timmermans HA, Achtman M, Hoogerhout P, Poolman JT. 1996. T-cell responses to outer membrane proteins of Neisseria meningitidis: comparative study of the Opa, Opc, and PorA proteins. Infect Immun 64:298-304.
44. Davenport V, Groves E, Horton RE, Hobbs CG, Guthrie T, Findlow J, Borrow R, Naess LM, Oster P, Heyderman RS, Williams NA. 2008. Mucosal immunity in healthy adults after parenteral vaccination with outer membrane vesicles from Neisseria meningitidis serogroup B. J Infect Dis 198:731-740. http://dx.doi.org/10.1086/590669.
45. Welsch JA, Rossi R, Comanducci M, Granoff DM. 2004. Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J Immunol 172:5606-5615. http://dx.doi.org/10.4049/jimmunol.172.9.5606.
46. Pollard AJ, Frasch C. 2001. Development of natural immunity to Neisseria meningitidis. Vaccine 19:1327-1346. http://dx.doi.org/10.1016/S0264-410X(00)00333-9.
47. Briere F, Servet-Delprat C, Bridon JM, Saint-Remy JM, Banchereau J. 1994. Human interleukin 10 induces naive surface immunoglobulin D(sIgDB cells to secrete IgG1 and IgG3. J Exp Med 179:757-762. http://dx.doi.org/10.1084/jem.179.2.757.
48. Naess LM, Aarvak T, Aase A, Oftung F, Høiby EA, Sandin R, Michaelsen TE. 1999. Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine. Vaccine 17:754-764. http://dx.doi.org/10.1016/S0264-410X(98)00259-X.
49. Vidarsson G, van der Pol W-L, van den Elsen JMH, Vilé H, Jansen M, Duijs J, Morton HC, Boel E, Daha MR, Corthésy B, van de Winkel JGJ. 2001. Activity of human IgG and IgA subclasses in immune defense against Neisseria meningitidis serogroup B. J Immunol 166:6250-6256. http://dx.doi.org/10.4049/jimmunol.166.10.6250.
50. Couper KN, Blount DG, Riley EM. 2008. IL-10: the master regulator of immunity to infection. J Immunol 180:5771-5777. http://dx.doi.org/10.4049/jimmunol.180.9.5771.
51. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. 2009. Regulatory T cells: how do they suppress immune responses? Int Immunol 21:1105-1111. http://dx.doi.org/10.1093/intimm/dxp095.
52. Davenport V, Groves E, Hobbs CG, Williams NA, Heyderman RS. 2007. Regulation of Th-1 T cell-dominated immunity to Neisseria meningitidis within the human mucosa. Cell Microbiol 9:1050-1061. http://dx.doi.org/10.1111/j.1462-5822.2006.00851.x.
53. Pollard AJ, Galassini R, Rouppe van der Voort EM, Hibberd M, Booy R, Langford P, Nadel S, Ison C, Kroll JS, Poolman J, Levin M. 1999. Cellular immune responses to Neisseria meningitidis in children. Infect Immun 67:2452-2463.